Abstract
Background
The aim of this study was to assess the selectivity of the studied xanthone derivatives for α1-adrenoceptor subtypes (α1A, α1B, α1D, α1L) in functional experiments in order to verify if they possess any selectivity for a distinct subtype of α1-adrenoceptor. Moreover, several pharmacological tests were carried out to assess whether they reveal other than α1-adrenoceptor blocking properties such as: antagonistic for 5-HT2 receptors, vasorelaxant or spasmolytic.
Methods
The influence on α1A-adrenoceptors was examined in biofunctional studies employing isolated rat vas deferens, on α1B-adrenoceptors in guinea-pig spleen, on α1D-adrenoceptors in rat aorta, and on α1L-adrenoceptors in rabbit spleen. Affinity for 5-HT2 receptors was measured in radioligand binding assay, whereas antagonistic potency for 5-HT2 receptors was studied on isolated rat aorta. Vasorelaxant effect of tested compounds was assessed in functional study employing rat aorta, whereas direct spasmolytic activity was investigated using the isolated rabbit small intestine.
Results
The present study provides evidences that the tested 2-methoxyphenylpiperazine xanthone derivatives are non-selective α1-adrenoceptor blockers. However, at higher concentrations the direct spasmolytic effect could enhance their hypotensive activity. The obtained results indicate that the studied xanthones possessed weak calcium entry blocking activity, as well as antagonistic properties for 5-HT2A receptors.
Conclusions
The results of the present study support the idea that the hypotensive activity of the studied compounds is related to their α1-adrenolytic properties.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cheng YW, Kang JJ. Mechanism of vasorelaxation of thoracic aorta caused by xanthone. Eur J Pharmacol 1997;336(1):23–8.
Jiang DJ, Dai Z, Li YJ. Pharmacological effects of xanthones as cardiovascular protective agents. Cardiovasc Drug Rev 2004;22(2):91–102.
Librowski T, Czarnecki R, Jastrzębska-Więsek M, Opoka W, Marona H. The influence of some aminoalkanolic xanthone derivatives on central nervous and cardiovascular systems in rodents. Boll Chim Farm 2004;143(7):267–74.
Lin CN, Chung MI, Liou SJ, Lee TH, Wang JP. Synthesis and anti-inflammatory effects of xanthone derivatives. J Pharm Pharmacol 1996;48(5):532–8.
Marona H, Szkaradek N, Rapacz A, Filipek B, Dybała M, Siwek A, et al. Preliminary evaluation of pharmacological properties of some xanthone derivatives. Bioorg Med Chem 2009;17(3):1345–52.
El-Seedi HR, El-Barbary MA, El-Ghorab DM, Bohlin L, Borg-Karlson AK, Gör-ansson U, et al. Recent insights into the biosynthesis and biological activities of natural xanthones. Curr Med Chem 2010;17(9):854–901.
Lin KW, Fang SC, Hung CF, Shieh BJ, Yang SC, Teng CM, et al. Synthesis, antiplatelet and vasorelaxing activities of xanthone derivatives. Arch Pharm (Weinheim) 2009;342(1):19–26.
Wang LW, Kang JJ, Chen IJ, Teng CM, Lin CN. Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives. Bioorg Med Chem 2002;10(3): 567–72.
Wang Y, Shi JG, Wang MZ, Che CT, Yeung JH. Mechanisms of the vasorelaxant effect of 1,5-dihydroxy-2,3-dimethoxy-xanthone, an active metabolite of 1-hydroxy-2,3,5-trimethoxy-xanthone isolated from a Tibetan herb, Halenia elliptica, on rat coronary artery. Life Sci 2008;82(1–2):91–8.
Wang Y, Shi JG, Wang MZ, Che CT, Yeung JH. Mechanisms of the vasorelaxant effect of 1-hydroxy-2,3,5-trimethoxy-xanthone, isolated from a Tibetan herb, Halenia elliptica, on rat coronary artery. Life Sci 2007;81(12):1016–23.
Santos CM, Silva AM, Filipe P, Santus R, Patterson LK, Mazie`re JC, et al. Structure-activity relationships in hydroxy-2,3-diarylxanthone antioxidants. Fast kinetics spectroscopy as a tool to evaluate the potential for antioxidant activity in biological systems. Org Biomol Chem 2011;9(10):3965–74.
Dai Z, Jiang DJ, Hu GY, Du YH, Yu J, Hu CP, et al. 3,4,5,6-Tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats. Cardiovasc Drugs Ther 2004;18(4):279–88.
Correia-da-Silva M, Sousa E, Duarte B, Marques F, Carvalho F, Cunha-Ribeiro LM, et al. Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. J Med Chem 2011;54(15):5373–84.
Marona H, Szkaradek N, Kubacka M, Bednarski M, Filipek B, Cegła M, et al. Synthesis and evaluation of some xanthone derivatives for anti-arrhythmic, hypotensive properties and their affinity for adrenergic receptors. Arch Pharm (Weinheim) 2008;341(2):90–8.
Szkaradek N, Rapacz A, Pytka K, Filipek B, Siwek A, Cegła M, et al. Synthesis and preliminary evaluation of pharmacological properties of some piperazine derivatives of xanthone. Bioorg Med Chem 2013;21(2):514–22.
Rapacz A, Pytka K, Sapa J, Kubacka M, Filipek B, Szkaradek N, et al. Antiar-rhythmic, hypotensive and α1-adrenolytic properties of new 2-methoxyphe-nylpiperazine derivatives of xanthone. Eur J Pharmacol 2014;735:10–6.
Chuliá S, Moreau J, Naline E, Noguera MA, Ivorra MD, D’Ocón MP, et al. The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta. Br J Pharmacol 1996;119(7):1305–12.
Sapa J, Kubacka M. The possible mechanism of hypotensive activity of some pyrrolidin-2-one derivatives with antagonist properties at alpha1-adrenoceptors. Eur J Pharmacol 2011;673:40–8.
Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. 1958. Br J Pharmacol 1997;120(Suppl. 4):151–61.
Kubacka M, Mogilski S, Filipek B, Marona H. The hypotensive activity and alpha1-adrenoceptor antagonistic properties of some aroxyalkyl derivatives of 2-methoxyphenylpiperazine. Eur J Pharmacol 2013;698(1–3):335–44.
Aboud R, Shafii M, Docherty JR. Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol 1993;109(1):80–7.
Eltze M, Grebe T, Michel MC, Czyborra P, Ullrich B. Affinity profile at alpha(1)-and alpha(2)-adrenoceptor subtypes and in vitro cardiovascular actions of (+)-boldine. Eur J Pharmacol 2002;443(1–3):151–68.
Czopek A, Byrtus H, Kołaczkowski M, Pawłowski M, Dybała M, Nowak G, et al. Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl-and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity. Eur J Med Chem 2010;45(4):1295–303.
Cheng YC, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973;22(23):3099–108.
Rapacz A, Sapa J, Bednarski M, Filipek B, Szkaradek N, Marona H. Antiarrhyth-mic activity of some xanthone derivatives with β1-adrenoceptor affinities in rats. Eur J Pharmacol 2014;738:14–21.
Hieble JP. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm Acta Helv 2000;74(2–3):163–71.
Jähnichen S, Eltze M, Pertz HH. Evidence that alpha(1B)-adrenoceptors are involved in noradrenaline-induced contractions of rat tail artery. Eur J Pharmacol 2004;488(1–3):157–67.
Cui Y, Zong H, Zhang Y. The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis. Int Urol Nephrol 2012;44(6):1601–9.
Buch J. Urapidil, a dual-acting antihypertensive agent: current usage considerations. Adv Ther 2010;27(7):426–43.
Dooley M, Urapidil Goa KL. A reappraisal of its use in the management of hypertension. Drugs 1998;56(5):929–55.
Ishizuka O, Imamura T, Kurizaki Y, Nishizawa O, Andersson KE. Male lower urinary tract symptoms and α1D-adrenoceptors. Int Urol Nephrol 2013;20(1):73–8.
Yamaguchi O. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. Int Urol Nephrol 2013;20(1):28–39.
Nelson PM, Harrod JS, Lamping KG. 5HT(2A) and 5HT(2B) receptors contribute to serotonin-induced vascular dysfunction in diabetes. Exp Diabetes Res 2012;2012:398406.
Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004;104(1):59–81.
Ogawa T, Sugidachi A, Tanaka N, Fujimoto K, Asai F. Pharmacological profiles of R-96544, the active formof anovel 5-HT2A receptor antagonist R-102444. Eur J Pharmacol 2002;457(2–3):107–14.
Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther 1999;290(3):1475–81.
Tamura K, Kanzaki T, Saito Y, Otabe M, Saito Y, Morisaki N. Serotonin (5-hydroxytryptamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT2 receptors. Atherosclerosis 1997;132(2):139–43.
Pinto MM, Sousa ME, Nascimento MS. Xanthone derivatives: new insights in biological activities. Curr Med Chem 2005;12(21):2517–38.
Chairungsrilerd N, Furukawa KI, Ohta T, Nozoe S, Ohizumi Y. Gamma-man-gostin, a novel type of 5-hydroxytryptamine 2A receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 1998;357(1):25–31.
Villazón M, Padín JF, Cadavid MI, Enguix MJ, Tristán H, Orallo F, et al. Functional characterization of serotonin receptors in rat isolated aorta. Biol Pharm Bull 2002;25(5):584–90.
Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268(4 Pt 1):C799–822.
Fang LH, Mu YM, Lin LL, Xiao PG, Du GH. Vasorelaxant effect of euxanthone in the rat thoracic aorta. Vasc Pharmacol 2006;45(2):96–101.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rapacz, A., Sapa, J., Nowiński, L. et al. Biofunctional studies of new 2-methoxyphenylpiperazine xanthone derivatives with α1-adrenolytic properties. Pharmacol. Rep 67, 267–274 (2015). https://doi.org/10.1016/j.pharep.2014.10.008
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2014.10.008